Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 45, Issue 4, pp 578–587 | Cite as

Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil

  • Renato D. Lopes
  • Patricia O. Guimarães
  • Mark Crowther
  • Elaine Hylek
  • Gilson S. Feitosa-Filho
  • Luiz E. Ritt
  • Nivaldo Filgueiras
  • David A. Garcia
Article
  • 75 Downloads

Abstract

To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Tenth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, on September 22 and 23, 2017. This scientific program was developed by clinicians for clinicians and was promoted by two major clinical research institutes—the Brazilian Clinical Research Institute and the Duke Clinical Research Institute of the Duke University School of Medicine. Comprising academic presentations and open discussion, the symposium had as its primary goal to educate, motivate, and inspire internists, cardiologists, hematologists, and other physicians by convening national and international visionaries, thought-leaders, and dedicated clinician-scientists. This paper summarizes the symposium proceedings.

Keywords

Thrombosis Antithrombotic therapy Guidelines Clinical research 

Notes

Compliance with ethical standards

Conflict of interest

RDL has received research grants from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, and Pfizer; and consulting fees from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, and Portola Pharmaceutical. POG declares that she has no conflict of interest. MC has served on a DSMB for Bayer, Daiichi; provided consulting for Octapharma, BMS Canada; received research support from Bayer, Pfizer, Heart and Stroke Foundation; and reports stock ownership in Alnylam. EH has served as a consultant or on an advisory board for Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Armetheon Daiichi Sankyo, Janssen, Medtronic Pfizer, and Portola. GSF-F, LER, and NF declare that they have no conflicts of interest. DAG has received research grants from Incyte, Janssen, and Daiichi Sankyo; and consulting fees from Incyte, Alexion, Janssen, Pfizer, Bristol-Myers Squibb, and Boehringer-Ingelheim.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    van Es N, Di Nisio M, Bleker SM et al (2015) Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 114:1268–1276CrossRefPubMedGoogle Scholar
  2. 2.
    Young A, Phillips J, Hancocks H et al (2016) OC-11 -anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb Res 140(Suppl 1):S172–S173CrossRefPubMedGoogle Scholar
  3. 3.
    Khorana AA, Carrier M, Garcia DA, Lee AY (2016) Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis 41:81–91CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest 149:315–352CrossRefPubMedGoogle Scholar
  5. 5.
    Francis CW, Kessler CM, Goldhaber SZ et al (2015) Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 13:1028–1035CrossRefPubMedGoogle Scholar
  6. 6.
    Chai-Adisaksopha C, Iorio A, Crowther MA et al. (2017) Vitamin K antagonists after 6 months of low-molecular-weight heparin in cancer patients with venous thromboembolism. Am J Med.  https://doi.org/10.1016/j.amjmed.2017.11.042. (Epub ahead of print)PubMedGoogle Scholar
  7. 7.
    Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW (2016) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 12:Cd008500PubMedGoogle Scholar
  8. 8.
    Khorana AA, Vadhan-Raj S, Kuderer NM et al (2017) Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. Rationale and design of the CASSINI trial. Thromb Haemost 117:2135–2145CrossRefPubMedGoogle Scholar
  9. 9.
    U.S. National Library of Medicine, ClinicalTrials.gov (2017) Apixaban for the prevention of venous thromboembolism in cancer patients (AVERT). https://www.clinicaltrials.gov/ct2/show/NCT02048865. Accessed 5 Feb 2018
  10. 10.
    van der Hulle T, den Exter PL, Planquette B et al (2016) Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost 14:105–113CrossRefPubMedGoogle Scholar
  11. 11.
    O’Connell C, Razavi P, Ghalichi M et al (2011) Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 9:305–311CrossRefPubMedGoogle Scholar
  12. 12.
    Di Nisio M, Lee AY, Carrier M, Liebman HA, Khorana AA (2015) Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 13:880–883CrossRefPubMedGoogle Scholar
  13. 13.
    Kuramatsu JB, Gerner ST, Schellinger PD et al (2015) Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313:824–836CrossRefPubMedGoogle Scholar
  14. 14.
    Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY (2015) Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 32:517–525CrossRefGoogle Scholar
  15. 15.
    Baker WL, Cios DA, Sander SD, Coleman CI (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15:244–252PubMedGoogle Scholar
  16. 16.
    Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMedGoogle Scholar
  17. 17.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891CrossRefPubMedGoogle Scholar
  18. 18.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  19. 19.
    Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104CrossRefPubMedGoogle Scholar
  20. 20.
    Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962CrossRefPubMedGoogle Scholar
  21. 21.
    Pokorney SD, Simon DN, Thomas L et al (2016) Stability of international normalized ratios in patients taking long-term warfarin therapy. JAMA 316:661–663CrossRefPubMedGoogle Scholar
  22. 22.
    Guimaraes PO, Kaatz S, Lopes RD (2015) Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. Int J Gen Med 8:283–291PubMedPubMedCentralGoogle Scholar
  23. 23.
    Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319–1330CrossRefPubMedGoogle Scholar
  24. 24.
    Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC (2012) Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126:1630–1639CrossRefPubMedGoogle Scholar
  25. 25.
    Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e326S–e350SCrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Clark NP, Witt DM, Davies LE et al (2015) Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med 175:1163–1168CrossRefPubMedGoogle Scholar
  27. 27.
    Doherty JU, Gluckman TJ, Hucker WJ et al (2017) 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American college of cardiology clinical expert consensus document task force. J Am Coll Cardiol 69:871–898CrossRefPubMedGoogle Scholar
  28. 28.
    Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962CrossRefPubMedGoogle Scholar
  29. 29.
    January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 64:e1–e76CrossRefPubMedGoogle Scholar
  30. 30.
    Forslund T, Wettermark B, Wandell P, von Euler M, Hasselstrom J, Hjemdahl P (2014) Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol 70:1477–1485CrossRefPubMedGoogle Scholar
  31. 31.
    Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125:2298–2307CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Renato D. Lopes
    • 1
  • Patricia O. Guimarães
    • 1
  • Mark Crowther
    • 2
  • Elaine Hylek
    • 3
  • Gilson S. Feitosa-Filho
    • 4
    • 5
    • 6
  • Luiz E. Ritt
    • 4
    • 7
  • Nivaldo Filgueiras
    • 8
    • 9
    • 10
    • 11
  • David A. Garcia
    • 12
  1. 1.Duke Clinical Research InstituteDuke University School of MedicineDurhamUSA
  2. 2.Department of MedicineMcMaster UniversityHamiltonCanada
  3. 3.Boston University Medical CenterBostonUSA
  4. 4.Escola Bahiana de Medicina e Saúde Pública (EBMSP)SalvadorBrazil
  5. 5.Hospital Santa Izabel - Santa Casa da BahiaSalvadorBrazil
  6. 6.Hospital Ana NerySalvadorBrazil
  7. 7.Hospital Cárdio PulmonarSalvadorBrazil
  8. 8.Universidade Salvador (UNIFACS) - rede LaureateSalvadorBrazil
  9. 9.Universidade do Estado da Bahia (UNEB)SalvadorBrazil
  10. 10.Fundação Bahiana de CardiologiaSalvadorBrazil
  11. 11.Hospital da CidadeSalvadorBrazil
  12. 12.Department of Medicine, University of Washington Medical CenterUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations